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Introduction
============

Cervical cancer is the leading cause of cancer related deaths among women in limited resource settings (about 230 000 deaths per year).[@ref1] In sub-Saharan Africa, age standardised annual incidence and mortality rates for invasive cervical cancer are 56 and 41 per 100 000 women, respectively, which are the highest rates in the world.[@ref2] Implementation of cytology based screening strategies has improved the control of cervical cancer in developed countries. Replicating these strategies in resource poor countries has been hampered by cost constraints, lack of infrastructures, insufficient health workforce, and lag time between sample collection and availability of test results.[@ref3]

The development of vaccines against human papillomavirus (HPV), a key cofactor of cervical cancer, was a major breakthrough for the prevention of cervical cancer. However, large scale implementation of HPV vaccination is still challenging, and even when effective, it will not override the need for cervical cancer screening.[@ref4] Thus, attention has been directed at new tests for cervical cancer screening that are appropriate for limited resource settings. Alternative methods to cytology have been developed, such as visual inspection of the cervix after application of acetic acid (VIA) or Lugol's iodine (VILI) and molecular testing for high risk types of HPV (HPV testing). These innovative methods can be combined with immediate or slightly delayed management of precursor lesions, and prevention strategies using these techniques are potentially viable and cost effective for reducing the incidence of invasive cervical cancer in resource poor countries.[@ref5] [@ref6] [@ref7] However, concerns about the effectiveness of screen and treat strategies in sub-Saharan Africa have recently emerged.[@ref8] Furthermore, the use of these novel tests for cervical cancer screening is not universally accepted.

Over the past few decades, many trials on cervical cancer prevention have been implemented in developing countries by the World Health Organization and partner organisations. In sub-Saharan Africa, most of these projects aimed to evaluate the feasibility and effectiveness of alternative methods for cervical cancer screening.[@ref9] Primary data from these studies have been conflicting, with some reports concluding that VIA was not suited for cervical cancer screening in sub-Saharan African countries.[@ref10] [@ref11] Previous reviews have looked at the accuracy of alternative screening methods for cervical cancer in resource poor countries, but none has focused on those in sub-Saharan Africa.[@ref12] [@ref13] [@ref14] [@ref15] Furthermore, comprehensive assessment of the quality of accuracy studies on cervical cancer screening conducted in the region has yet to be performed. To evaluate the reliability of results obtained from concluded or ongoing projects and to facilitate their implementation, we conducted a systematic review and meta-analysis to assess the accuracy of VIA, VILI, and HPV testing as standalone tests for primary screening for cervical cancer in sub-Saharan Africa.

With this systematic review and meta-analysis, we aimed to answer three questions in relation to VIA, VILI, and HPV testing:

-   What is the validity (risk of bias and applicability) of accuracy studies on the three techniques when applied independently for primary cervical cancer screening in sub-Saharan Africa?

-   What is the prevalence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and positivity rate of these screening methods in sub-Saharan Africa?

-   What is the overall performance (sensitivity, specificity, positive predictive value, and negative predictive value) of the screening methods to detect high grade cervical lesions, and how do they compare with each other in sub-Saharan Africa?

Methods
=======

Data sources and studies selection
----------------------------------

We did a computerised literature search for studies and technical reports published between January 1994 and June 2014, on Medline (via PubMed), Embase, Google Scholar, Scopus, the Cochrane Library, OCLC (Paper First and Proceedings First), PAIS International Database (EBSCO), WHO Global Health Library, and POPLINE. The concept of "alternative methods" for cervical cancer screening was introduced in 1994. Web appendix 1 shows the PICOS components (population, intervention, comparison, outcomes, and studies) of this review. We used a combination of medical subject heading terms and free text terms relating to "cervical cancer," "screening," and "sub-Saharan Africa," limiting to studies in human beings (web appendix 2). We also searched the databases of Web of Knowledge and scanned the references lists of relevant reviews. We made no restriction by publication language or study design. The last search date was 11 July 2014.

Studies identified were sequentially screened by title, abstract, and full text to retain those in the final review. Included studies met the following criteria:

-   Alternative methods of cervical cancer screening (VIA, VILI, or HPV testing) were used as standalone tests for primary screening

-   The study population was not at particular risk of cervical cancer (studies focusing on HIV positive women or on women presenting with gynecological symptoms were excluded)

-   The screening procedure was performed by paramedical healthcare providers (excluding physicians)

-   The reference test was either random biopsies or colposcopy guided biopsies, loop excision, or endocervical curettage performed at least in screen positive women.

For HPV testing, studies were eligible if sampling was done by the provider (that is, excluding self sampling) and if the technique for HPV detection was either polymerase chain reaction (PCR) or second generation hybrid capture because the first generation assay is no longer available. Authors of relevant studies were contacted for missing data. Web appendix 3 lists the excluded studies after review of the abstract or methods of full texts and the reasons for exclusion.

Definition of positive screening tests
--------------------------------------

Visual methods (VIA and VILI) involved examination of the cervix with the naked eye (without magnification) using a focus lamp or a torch light. In the most recent studies, VIA and VILI were categorised as positive or negative according to the criteria of the International Agency for Research on Cancer (IARC).[@ref16] But in earlier studies, the mere presence of an acetowhite lesion or growth on the cervix was considered positive for VIA. A positive result to VIA from IARC criteria was defined as the presence of well defined acetowhite areas in the transformation zone (near the squamocolumnar junction or external os) or the presence of an acetowhite growth, about one minute after direct application of a 3-5% diluted solution of acetic acid using a cotton swab or a spray. A positive result to VILI was based on the appearance of a definite yellow area in the transformation zone, close to the squamocolumnar junction or the external os or on a cervical growth, after application of a 5% solution of Lugol's iodine.

For HPV testing, most studies carried out in sub-Saharan Africa used the second generation hybrid capture system, or a spin-off system known as careHPV. Results from either system were scored as positive if the ratio of specimen relative light units (RLUs) was equal to or greater than the reference RLU (1 pg/mL). The other method for HPV detection included in this review was the PCR technique for which we kept the definition of positive results as defined by the tests manufacturers.

Definition of disease and gold standard
---------------------------------------

Disease was defined as the presence of histologically confirmed CIN2+ or equivalent according to the WHO classification.[@ref17] The reference standard test (or gold standard) that we initially selected for this review was either a combination of colposcopy and histology, or histology without colposcopy. However, no study using histology without colposcopy as a gold standard fulfilled our inclusion criteria. In most studies, biopsy or loop excision was performed if a lesion was suspected at colposcopy, and endocervical curettage, random biopsies, or no histological sampling was done if there was no visible lesion or squamocolumnar junction.

Management of screened women
----------------------------

The management of women across selected studies when reported was based on the results of screening and reference tests. When colposcopic findings or biopsy results showed the presence of high grade cervical dysplasia, women generally received cryotherapy (in recent studies), cauterisation (in earlier studies), or conisation (loop electrosurgical excision procedure or cold knife conisation) as indicated. If the histological interpretation was suggestive of invasive cervical cancer, patients were referred to a specialised centre for disease assessment and appropriate treatment (hysterectomy, radiotherapy, or chemotherapy when necessary). Women who screened negative and those presenting minor grade cervical lesions on colposcopy or biopsy were advised to repeat screening within the next three years.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in the design and implementation of the study. There are no plans to involve patients in dissemination.

Data abstraction and quality assessment
---------------------------------------

Our protocol followed the PRISMA guidelines[@ref18] (web appendix 4). Two reviewers independently screened studies for eligibility and extracted data for inclusion in this systematic review. We extracted the following data: first author's name, year of publication, study period, country, geographical area (middle Africa, eastern Africa, western Africa, and southern Africa; web figure 1, web appendix 5), study design, study population, sample size, age range, screening test(s) assessed, qualification of screeners, place of screening (field clinic, primary and tertiary levels), definition of positive screening results, type of screening test (for HPV testing), gold standard or reference test, disease thresholds, and recipients of the reference test.

If many study samples from different countries were included in a single report and data were provided separately, we treated each sample as an individual study. For each screening test per study, we extracted data for the number of true positives, false negatives, false positives, and true negatives as defined by the threshold of CIN2+. Studies were classified into two groups, depending on whether the gold standard was performed in all women (GSA) or only in a portion of the study population that included all women with positive screening results (GSP). For the second group, we assumed that women who screened negative and did not undergo reference standard were disease free.[@ref19] Two investigators separately evaluated the quality of eligible studies with the quality assessment of diagnostic accuracy studies 2 (QUADAS-2) checklist.[@ref20] Disagreements were solved by consensus.

Data synthesis
--------------

We pooled prevalence of disease (CIN2+) by screening test (VIA, VILI, or HPV testing), geographical region, study group (GSA or GSP), and positivity rate (proportion of screen positive women in the study population) of each screening test by study group using random effects meta-analytical methods for proportions with arcsine transformation.[@ref21] Heterogeneity across studies was assessed and quantified with the Cochran Q test and I^2^ statistic.[@ref22] Absolute accuracy measures (sensitivity, specificity) were pooled by screening group in a bivariate random effects model, allowing for inter-setting variability.[@ref23] We jointly illustrated the absolute pooled sensitivity and specificity for CIN2+ using hierarchical summary receiver operating characteristic (HSROC) regression curves.[@ref24] [@ref25] In the GSA group, we used meta-regression approach within the bivariate model[@ref26] to explore the following studies characteristics as potential sources of heterogeneity in test performance: year of publication, sample size, geographical area, and place of screening. Taking into account the variation of disease prevalence across studies and their pooled values within each geographical area, we computed negative and positive predictive values for each screening test from the pooled estimates of sensitivity and specificity using Bayes' theorem.

The pooled relative sensitivities and specificities of either screening test versus another were obtained from the pooled absolute accuracy measures assessed by a bivariate model with the method of moments,[@ref27] allowing for inter-setting variability. This analysis was based on indirect comparisons, because the relative accuracy measures were obtained from aggregate estimates across all studies that contributed any sensitivity or specificity for either test. Because the within study correlation was unknown, we defined three scenarios in which correlation between sensitivities assessed for different screening tests in the same study was low (0), medium (0.5), and high (0.8). The value of the correlation had little effect on pooled relative sensitivities; therefore, we only presented results assuming a correlation of 0, which are slightly conservative.

To assess the robustness of our results, a leave one out sensitivity analysis of the pooled estimates of relative sensitivity and specificity, disease prevalence, and tests' positivity rate were pooled with the double arcsine transformation of Freeman-Tukey.[@ref28] For the relative accuracy estimates, we also made direct comparisons by restricting analyses to studies that assessed pairs of tests. Publication bias was assessed by funnel plots of the diagnostic odds ratios, as well as the trim and fill method.[@ref29] We used Egger's test to detect a potential association between the precision and the value of the estimates.

We defined statistical significance as P\<0.05 for two sided tests. All statistical analyses were performed with the R packages metafor version 1.9.3 for meta-analysis of prevalence and positivity rates,[@ref30] mada version 0.5.5 for bivariate meta-analysis of sensitivity and specificity,[@ref31] and mvmeta version 0.4.4 for assessing pooled relative sensitivities and specificities.[@ref32]

Results
=======

Study characteristics
---------------------

Of 1049 entries identified via searches, 15 papers (eight in the GSA group, seven in the GSP group) fulfilled the inclusion criteria[@ref19] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] (fig 1[](#fig1){ref-type="fig"}). Two thirds of included papers were from southern (six papers) or eastern (four) Africa. One article reported data from five countries in western and middle Africa;[@ref40] we considered them separately. Therefore, the meta-analyses included 15 reports (10 in the GSA group; five in the GSP group) of 61 381 women screened by VIA, eight reports (all GSA) of 46 435 women screened by VILI, and six reports (three GSA; three GSP) of 11 322 women screened by HPV testing (four on second generation hybrid capture assays, one on careHPV, and one on PCR).

![**Fig 1** Study flowchart of papers in selection process. \*Gold standard performed in all women in the study population. †Gold standard performed in all women with a positive screening result and only a portion of women with a negative screening result. HC2=second generation hybrid capture assay; PICOS=population, intervention (screening tests), comparison (gold standard), outcomes (absolute and relative sensitivity and specificity, prevalence of CIN2+, and positivity rate of tests), study design; PCR=polymerase chain reaction; RCT=randomised controlled trial](domj024615.f1_default){#fig1}

Included women were more likely to be rural dwellers, previously unscreened, and asymptomatic. Women attending primary health centres for non-gynecological symptoms were recruited in two studies;[@ref34] [@ref37] in another study, participants were reported to be healthy women attending an urban family planning clinic (84%), and a small proportion of women (16%) referred for gynecological complaints.[@ref38] Age of participants across studies ranged from 15 to 83 years. Screeners were more often nurses, whereas colposcopic examination, punch biopsy, loop excision, or endocervical curettage when indicated were done by trained physicians. Histological interpretation of biopsies was provided by skilled pathologists. Table[](#tbl1){ref-type="table"} presents a summary of study characteristics.

###### 

Characteristics of included studies

  Study                        Publication year   Screening test(s)   Country        No of women     Screener   Place of screening   Gold standard category   HPV testing technique
  ---------------------------- ------------------ ------------------- -------------- --------------- ---------- -------------------- ------------------------ -----------------------
  Megevand^33^                 1996               VIA                 South Africa   2426            Nurse      Field clinic         GSP                      ---
  University of Zimbabwe^34^   1999               VIA                 Zimbabwe       2130            Nurse      Primary              GSA                      ---
  Denny^35^                    2000               VIA                 South Africa   2944            Nurse      Field clinic         GSP                      ---
  Wright^36^                   2000               HPV testing         South Africa   1365            Nurse      Primary              GSP                      HC2
  Kuhn^38^                     2000               HPV testing         South Africa   2861            Nurse      Primary              GSP                      HC2
  Womack^37^                   2000               HPV testing         Zimbabwe       2145            Nurse      Primary              GSA                      HC2
  Denny^39^                    2002               VIA                 South Africa   2698            Nurse      Field clinic         GSP                      ---
  Sankaranarayan^40^           2004               VIA/VILI            Burkina        2051/2051       Nurse      Field clinic         GSA                      ---
  Sankaranarayan^40^           2004               VIA/VILI            Congo          6935/6935       Nurse      Field clinic         GSA                      ---
  Sankaranarayan^40^           2004               VIA/VILI            Guinea         7462/7462       Nurse      Field clinic         GSA                      ---
  Sankaranarayan^40^           2004               VIA/VILI            Mali           5552/5552       Nurse      Field clinic         GSA                      ---
  Sankaranarayan^40^           2004               VIA/VILI            Niger          1827/1827       Nurse      Field clinic         GSA                      ---
  H De Vuyst^41^               2005               VIA/HPV testing     Kenya          653/453         Nurse      Tertiary             GSA                      PCR
  Sangwa-Lugoma^42^            2006               VIA/VILI            Congo          1528/1528       Nurse      Primary              GSA                      ---
  Muwonge^43^                  2010               VIA/VILI            Angola         8849/8842       Nurse      Primary              GSA                      ---
  Ngoma^44^                    2010               VIA/VILI            Tanzania       10 374/10 367   Nurse      Primary              GSA                      ---
  Mahmud^46^                   2012               HPV testing         Congo          1352            Nurse      Primary              GSA                      HC2
  Ahmed Ibrahim^45^            2012               VIA                 Sudan          934             Nurse      Primary              GSP                      ---
  Jeronimo^19^                 2014               VIA/HPV testing     Uganda         3146/3146       Nurse      Tertiary             GSP                      careHPV

HC2=second generation hybrid capture assay; Gold standard=colposcopy followed by colposcopy directed biopsies; GSA=gold standard performed in all women of the study population; GSP=gold standard performed in screen positive women and only a portion of screen negative women; PCR=polymerase chain reaction.

Assessment of studies quality
-----------------------------

Overall, the 15 selected papers were methodologically of moderate quality. Poor grades for the 13 QUADAS items ranged from 15% (two items) to 54% (seven), equivocal grades from 8% (one) to 39% (five), and good grades from 23% (three) to 77% (10; web table 2, web appendix 5). Concerning participants' selection, risk of bias was low in 40% (six papers) of the studies and unclear in 60% (nine); concerns on applicability were small in 93% (14) and major in 7% (one) of the studies. In the conduct and interpretation of screening tests, overall risk of bias was low in 14 (93%) studies and unclear in one (7%); suitability for our review was estimated to be good in nine (60%) studies, unclear in two (13%), and poor in four (27%).

The imperfect gold standard bias was present in all studies, because the reference test was a combination of colposcopy and histology. Although the histological results were interpreted without knowledge of the index test's results in 60% of studies, this information was not available in 40% of studies. The risk of incorporation bias was greater in studies evaluating the accuracy of visual methods than in studies evaluating the accuracy of HPV testing. Applying the reference test to our research question was slightly problematic in all but one study.[@ref41] The time interval between completion of the index test and confirmation with the reference test was shorter than one month in 12 (80%) of the 15 studies, longer than one month in two studies (13%), and unreported in one study (7%). The risk of ascertainment bias was lower in studies of the GSA group than in those of the GSP group (53% *v* 47%). Reasons for excluding participants were reported in nine studies (60%) and not given in six studies (40%). Most reports did not provide enough information about uninterpretable results for the index test (13 articles, 87%), and up to half of studies did not clearly mention uninterpretable results of the reference test (seven papers, 47%).

Quality assurance of the reference test was carried out and reported in six studies (all conducted under the auspices of the IARC); quality control was conducted internally (regular onsite assessment and retraining of colposcopists and pathologists throughout the project) and externally (review of slides in a reference laboratory). In eight studies, histological samples were shipped to and analysed by skilled pathologists in the United States, Canada, and Belgium, but quality assurance was not mentioned except for in one report where histological interpretation was performed independently by two pathologists. The remaining six studies did not provide information on quality assurance of the reference test.

Prevalence of CIN2+ and positivity of screening tests
-----------------------------------------------------

Table 2[](#tbl2){ref-type="table"} summarises the pooled estimates of disease prevalence and positivity rate of screening tests by study group; web appendix 6 shows the forest plots. Four studies (three GSA, one GSP) reported prevalence higher than 8%, whereas the other studies reported it below 6%. The pooled prevalence varied by geographical region (P=0.03; 2.0% (95% confidence interval 1.2% to 2.9%) in western Africa, 2.5% (0.8% to 5.1%) in middle Africa, 3.7% (2.4% to 5.3%) in southern Africa, and 6.2% (2.9% to 10.5%) in eastern Africa). In the GSA group, there was no significant difference in the pooled prevalence of CIN2+ between HPV testing and VIA studies (6.9% *v* 3.3%, P=0.24) and between HPV testing and VILI studies (6.9% *v* 2.3%, P=0.10; table 2)**.**

###### 

Prevalence of disease (CIN2+) and positivity rate of VIA, VILI, and HPV testing in sub-Saharan Africa

  Test and subgroup   No of studies   Prevalence of CIN2+                    Positivity rate                         
  ------------------- --------------- --------------------- ---------------- ----------------- --------------------- ----------------
  **VIA**                                                                                                            
  GSA                 10              3.3 (2.1 to 4.7)      98.4, P\<0.001                     17.4 (10.4 to 25.6)   99.8, P\<0.001
  GSP                 5               3.5 (2.1 to 5.4)      96.0, P\<0.001                     15.8 (6.0 to 29.0)    99.7, P\<0.001
  P†                  ---             0.82                  ---                                0.83                  ---
  All studies         15              3.4 (2.4 to 4.4)      97.9, P\<0.001                     16.8 (11.0 to 23.6)   99.8, P\<0.001
  **VILI**                                                                                                           
  (all GSA)           8               2.3 (1.5 to 3.3)      97.6, P\<0.001                     16.5 (9.8 to 24.7)    99.8, P\<0.001
  **HPV testing**                                                                                                    
  GSA                 3               6.9 (1.7 to 15.2)     98.4, P\<0.001                     31.4 (11.5 to 55.8)   99.5, P\<0.001
  GSP                 3               3.3 (2.6 to 4.0)      62.2, P=0.0708                     20.7 (19.1 to 22.4)   66.3, P=0.0516
  P†                  ---             0.23                  ---                                0.34                  ---
  All studies         6               4.9 (2.7 to 7.8)      97.4, P\<0.001                     25.8 (17.4 to 35.3)   99.2, P\<0.001

I^2^=heterogeneity index; GSA=gold standard (colposcopy and directed biopsies) performed in all women of the study population; GSP=gold standard performed in a portion of the study population, including all women who screened positive.

\*P value from the Cochran's Q test for detecting heterogeneity.

†P value for comparison between subgroups.

The pooled positivity rate of VIA was 16.8% (95% confidence interval 11.0% to 23.6%) and ranged between 3.1% and 39.9%. Likewise, the pooled positivity rate for VILI was 16.5% (9.8% to 24.7%), with the highest value in Angola (32.0%) and the lowest value in Tanzania (4.8%). The positivity rate for HPV testing varied from 12.5% in the Democratic Republic of Congo (DRC) to 42.8% in Zimbabwe, with a pooled estimate of 25.8% (17.4% to 35.3%). Overall, included studies were highly heterogeneous with respect to disease prevalence and positivity rate of the screening tests (table 2).

Accuracy of VIA, VILI, and HPV testing
--------------------------------------

Figure 2[](#fig2){ref-type="fig"} shows the variation of absolute sensitivity and specificity of VIA, VILI, and HPV testing in detecting CIN2+ in the GSA group. The pooled sensitivity for VIA in this group was 82.4% (95% confidence interval 76.3% to 87.3%) and ranged between 65.0% (40.8% to 84.6%) in Mali and 94.4% (90.6% to 97.0%) in Tanzania. The pooled specificity of VIA was 87.4% (77.1% to 93.4%), with the lowest value observed in Zimbabwe (64.1%, 61.9% to 66.2%) and the highest in Tanzania (98.2%, 98.0% to 98.5%).

![**Fig 2** Absolute sensitivity and specificity of VIA, VILI, and HPV testing for CIN2+ detection in sub-Saharan Africa. Diamond=95% confidence interval of the pooled measure computed with a bivariate random effects model. This figure includes only studies where the gold standard (colposcopy and colposcopy directed biopsies) was performed in all women of the study population (that is, GSA group). Heterogeneity across studies was assessed with Cochran's Q test for each screening test (all P\<0.05). DRC=Democratic Republic of Congo](domj024615.f2_default){#fig2}

For VILI, absolute sensitivity varied between 72.4% (confidence interval 52.8% to 87.3%) in DRC and 99.1% (96.9% to 99.9%) in Tanzania, whereas specificity ranged from 73.1% (71.1% to 75.0%) in Burkina Faso to 97.3% (97.0% to 97.6%) in Tanzania. The pooled sensitivity of VILI (95.1%, 90.1% to 97.7%) was significantly higher than that for VIA in the GSA group. However, the pooled specificity of VILI (87.2%, 78.1% to 92.8%) was not different from that for VIA.

Pooled absolute sensitivity of HPV testing was 88.3% (confidence interval 73.1% to 95.5%), with the lowest estimate (80.2%, 74.1% to 85.4%) observed in Zimbabwe and the highest value (96.2%, 87.0% to 99.5%) found in the only study that used PCR for HPV detection, in Kenya.[@ref41] Absolute specificity of HPV testing varied between 61.2% (59.0% to 63.4%) in Zimbabwe and 88.9% (87.0% to 90.5%) in DRC, with a pooled value of 73.9% (50.7% to 88.7%). The pooled sensitivity and specificity of HPV testing were not different from those for VIA (both P≥0.23) and VILI (both P≥0.16).

Table 3[](#tbl3){ref-type="table"} shows the pooled relative sensitivity and specificity of each test versus others using indirect comparisons. This ratio confirms that pooled absolute sensitivity for VIA was significantly lower than for VILI, because the relative sensitivity of VIA versus VILI (0.86, 95% confidence interval 0.82 to 0.90, P\<0.001) was significantly lower than 1. However, relative sensitivity between VIA and HPV (0.94, 0.82 to 1.16) and between VILI and HPV (1.08, 0.98 to 1.30) was not significantly different from 1 (both P≥0.14). Pooled specificity was similar for VIA and VILI: relative specificity was 1.01 (0.90 to 1.13, P=0.85). Moreover, pooled specificity for HPV testing was lower than for VIA and VILI but not significantly, with relative values of 1.17 (0.95 to 1.69, P=0.15) and 1.18 (0.96 to 1.71, P=0.15), respectively.

###### 

Pooled relative sensitivity and specificity of VIA, VILI, and HPV testing for CIN2+ detection in sub-Saharan Africa based on indirect comparisons

                         No of studies   Relative sensitivity (95% CI)\*   Relative specificity (95% CI)\*
  ---------------------- --------------- --------------------------------- ---------------------------------
  VIA *v* VILI           10 *v* 8        0.86 (0.82 to 0.90)               1.01 (0.90 to 1.13)
  VIA *v* HPV testing    10 *v* 3        0.94 (0.82 to 1.16)               1.17 (0.95 to 1.69)
  VILI *v* HPV testing   8 *v* 3         1.08 (0.98 to 1.30)               1.18 (0.96 to 1.71)

\*Ratios higher than 1 indicate greater sensitivity or specificity of the first test, whereas ratios lower than 1 indicate lower sensitivity or specificity of the first test. When 95% confidence intervals do not include the unity, the difference in sensitivity or specificity between tests is statistically significant.

Figure 3[](#fig3){ref-type="fig"} shows the joint variation of observed and pooled sensitivity and specificity by screening test in the GSA group. The wide area of the confidence ellipse for HPV testing reflects the small number of accuracy studies conducted on HPV testing in sub-Saharan Africa. Curves for VILI are closer to the upper left corner of the rectangle than those for VIA, without overlapping ellipses between the two tests (fig 3). These results underpin the better performance of VILI compared with VIA for primary screening of cervical cancer in sub-Saharan Africa.

![**Fig 3** Absolute accuracy of VIA, VILI and HPV testing for primary cervical cancer screening in sub-Saharan Africa. HSROC=hierarchical summary receiver operating characteristic regression curves. HSROC curves depict the fitted sensitivity as a function of specificity for VIA, VILI, HPV testing, and all three tests combined to detect CIN2+. These curves include only studies where gold standard (colposcopy and colposcopy directed biopsies) was applied to all women (that is, GSA group). Small blue squares, red circles, and green triangles and grey line circles=individual studies and 95% confidence ellipses; large blue squares, red circles, and green triangles and circles=pooled sensitivity and specificity and 95% confidence ellipses](domj024615.f3_default){#fig3}

Heterogeneity factors of screening tests accuracy
-------------------------------------------------

Although accuracy measures showed large inconsistencies among studies for all screening tests (most P\<0.05 for the Cochran Q tests), the I^2^ heterogeneity index was generally lower for HPV testing. Potential sources of variability were analysed in the GSA group for VIA and VILI (table 4[](#tbl4){ref-type="table"}). VIA and VILI accuracy did not vary by geographical area or by place of screening. However, the specificity for VIA was higher in recent studies than in older ones when definition of VIA was less precise. Moreover, sensitivity of VIA and VILI and specificity of VIA to detect CIN2+ increased significantly with the sample size, which we considered as a proxy for screening experience. The few number of studies in the GSA group (n=3) precluded reliable heterogeneity analyses for HPV testing.

###### 

Analysis of heterogeneity factors in assessing accuracy of VIA and VILI in sub-Saharan Africa

  ----------------------------- ----------------------------- ---------------------------------- ------- ----------------------------- ---------------------------------- -------
  **Factors (no of studies)**   **Sensitivity (%; 95% CI)**   **Adjusted odds ratio (95% CI)**   **P**   **Specificity (%; 95% CI)**   **Adjusted odds ratio (95% CI)**   **P**
  **VIA**                                                                                                                                                                 
  Geographical area                                                                                                                                                       
   Middle Africa (n=3)          80.0 (76.4 to 83.1)           1 (reference)                      ---     82.4 (55.5 to 94.6)           1 (reference)                      ---
   Western Africa (n=4)         84.0 (70.8 to 91.9)           1.35 (0.49 to 3.92)                0.53    90.2 (80.6 to 95.4)           1.97 (0.29 to 13.30)               0.49
   Eastern Africa (n=3)         85.1 (66.8 to 94.2)           1.45 (0.49 to 4.26)                0.50    87.5 (46.8 to 98.2)           1.49 (0.19 to 11.51)               0.70
  Place of screening\*                                                                                                                                                    
   Field clinic (n=5)           83.0 (73.7 to 89.5)           1 (reference)                      ---     88.2 (78.2 to 94.0)           1 (reference)                      ---
   Primary (n=4)                83.3 (69.4 to 91.7)           1.03 (0.42 to 2.50)                0.95    88.2 (77.3 to 94.3)           1.01 (0.18 to 5.47)                0.99
  Sample size† (n=10)           ---                           1.13 (1.03 to 1.23)                0.01    ---                           1.28 (1.10 to 1.48)                0.001
  Publication year‡ (n=10)      ---                           1.07 (0.95 to 1.21)                0.24    ---                           1.26 (1.04 to 1.53)                0.02
  **VILI**                                                                                                                                                                
  Geographical area§                                                                                                                                                      
   Middle Africa (n=3)          90.4 (73.6 to 97.0)           1 (reference)                      ---     78.9 (66.4 to 89.0)           1 (reference)                      ---
   Western Africa (n=4)         96.9 (93.9 to 98.5)           2.62 (0.68 to 10.09)               0.16    87.5 (92.9 to 78.9)           1.86 (0.70 to 4.97)                0.21
  Place of screening                                                                                                                                                      
   Field clinic (n=5)           96.4 (94.2 to 97.8)           1 (reference)                      ---     87.8 (81.5 to 92.1)           1 (reference)                      ---
   Primary (n=3)                94.2 (64.8 to 99.3)           0.66 (0.13 to 3.41)                0.62    86.1 (51.9 to 97.3)           1.16 (0.28 to 4.86)                0.84
  Sample size† (n=8)            ---                           1.32 (1.12 to 1.57)                0.001   ---                           1.14 (0.94 to 1.38)                0.18
  Publication year‡ (n=8)       ---                           1.09 (0.79 to 1.51)                0.61    ---                           1.03 (0.79;1.36)                   0.81
  ----------------------------- ----------------------------- ---------------------------------- ------- ----------------------------- ---------------------------------- -------

\*The place of screening was tertiary for one study, which was omitted in the analysis.

†Adjusted odds ratio per 1000 additional trial participants.

‡Adjusted odds ratio per additional year.

§Only one VILI study was located in eastern Africa, which was omitted in the analysis.

Sensitivity analyses and publication bias assessment
----------------------------------------------------

In a leave one out sensitivity analysis, relative specificity of VIA versus HPV testing increased to 1.41 (95% confidence interval 1.26 to 1.54, P\<0.001) when the study by Mahmud and colleagues[@ref46] was removed. Specificity of HPV testing in this study was largely higher (88.9%) than in the other two studies (61.2% and 64.5%), and its exclusion resulted in a decrease in the pooled absolute specificity from 73.9% (95% confidence interval 50.7% to 88.7%) to 62.1% (59.0% to 64.9%). Furthermore, the relative sensitivity of VILI versus HPV testing was significantly different from 1 (1.18, 1.09 to 1.27, P\<0.001) when the only study that used PCR for HPV detection[@ref41] was removed, with the pooled absolute sensitivity of HPV testing decreasing from 88.3% (73.1% to 95.5%) to 80.8% (75.2% to 85.5%). Statistical significance was also achieved (1.09, 1.00 to 1.31, P=0.04) when the study by Sangwa-Lugoma and colleagues[@ref42] was removed, with the absolute sensitivity of VILI moving from 95.1% (90.1% to 97.7%) to 96.2% (94.0% to 97.6%).

Changes in other estimates were, in general, non-significant and clinically trivial. When we restricted analyses of the relative accuracy of screening tests to studies based on paired tests (direct comparisons), the results were consistent with those obtained by indirect comparisons except for the relative sensitivity between VIA and HPV testing (0.77 (95% confidence interval 0.63 to 0.89); P=0.004) that was based on a single study. No evidence of publication bias was found across VIA and VILI studies. Moreover, no asymmetry in the funnel plot of diagnostic odds ratios for VIA and VILI was detected by Egger's test (both P≥0.35). With the trim and fill approach, no study was missing for the funnel plot to be symmetric. Publication bias was not investigated for HPV testing, owing to the small number of studies. Finally, implementing variance stabilisation via double arcsine transformations had no meaningful effect on pooled prevalence and positivity rate estimates.

GSP studies
-----------

In the GSP group, four studies evaluated VIA, three HPV testing, and one both VIA and HPV testing. Pooled prevalence (P=0.82 for VIA and P=0.23 for HPV testing) and positivity rate (P=0.83 for VIA and P=0.34 for HPV testing) did not differ significantly between GSA and GSP groups (table 2). The pooled sensitivity of VIA in detecting CIN2+ was lower in GSP studies than in GSA studies (68.6% *v* 82.4%, P=0.009), while the specificity was similar (87.4% *v* 89.8%, P=0.73). No significant difference was found for sensitivity and specificity of HPV testing (P=0.56 and P=0.39, respectively) among the two groups. Web appendices 6 and 7 show variation of CIN2+ prevalence, positivity rate, sensitivity and specificity across studies of the GPS group.

Discussion
==========

Main findings
-------------

Results from this meta-analysis suggest that in the context of primary cervical cancer screening in sub-Saharan Africa, VILI seems to be the most accurate alternative to cytology. When performed by nurses, VILI was about 13% more sensitive than and as specific as VIA in this region. VILI was about 7% more sensitive and 13% more specific than HPV testing, although the difference was not significant.

In resource limited settings, highly sensitive tests are critical to ensure effectiveness of screening programmes by allowing early detection of cervical cancer cases and reducing the need to repeat tests at shorter intervals. In addition, screening tests should be minimally invasive and results should be provided as soon as possible to allow rapid treatment of lesions and minimise the duration and the number of visits. These requirements that might increase adhesion of women to screening are important in sub-Saharan Africa, where strategies based on less frequent screenings seem to be more appropriate. Although not currently recommended by WHO for cervical cancer screening, VILI probably meets the above requirements better than VIA in sub-Saharan Africa.

Interpretation of results
-------------------------

Many reasons could explain the better performance of VILI in sub-Saharan Africa. Compared with VIA, lesions on VILI were judged less equivocal and easily recognised by investigators in Africa.[@ref47] Even experienced African colposcopists have found that colour changes yielded by iodine impregnation of cervical mucosa are more easily detectable than acetowhite switches observed after application of acetic acid.[@ref42] When these tests are performed with the naked eye---by nurses and with lighting probably less adequate than that produced by colposcopes---VILI is understandably preferred to and more accurate than VIA in sub-Saharan Africa. Furthermore, the absence of a time gap between application of iodine on the cervix and appearance of mustard yellow lesion, the greater stability and persistence of lesions, and the reduced need for repeated soaking of the cervix with iodine, partly explain why screeners in Africa are more comfortable with VILI. However, interpretation of VILI is difficult in postmenopausal women, because non-glycogenated atrophied cervical mucosa does not take up iodine and appears yellowish.[@ref13]

The high absolute accuracy estimates of VIA and VILI reported in included studies can be explained by several reasons. In most studies, the reference investigations were applied by newly trained clinicians in techniques such as colposcopy and directed biopsy, and their learning curves possibly evolved as studies progressed. At most study locations, there was either no or limited previous screening and colposcopy experiences, and providers were most often rapidly trained when the studies were initiated. Similarly, the pathologists involved in the studies probably overcalled CIN 2+ lesions because of their limited experience, recent reorientation, and lack of adequate quality assurance. Moreover, the correlation between visual techniques (VIA, VILI, and colposcopy) might have been another contributory factor. Finally, because most women had never been previously screened, the lesions detected might have been larger in size.

Evaluation of HPV testing's accuracy in this meta-analysis was less precise than that of VIA and VILI, since only three studies in the GSA group fulfilled our inclusion criteria. Furthermore, this review did not include studies of HPV testing on self obtained specimens and could not assess the effect of the sampling device (tampon, brush, lavage, or swab) on test accuracy. The lower interstudy variability for this molecular method could be explained by the fewer reports analysed, but it might also reflect the higher reproducibility of HPV test results, which are not or slightly dependent on the screener. Moreover, only one study using the careHPV assay (which has been designed for use in limited resource settings such as sub-Saharan Africa) was eligible. Although primary results from studies conducted in Asia are promising,[@ref48] [@ref49] [@ref50] [@ref51] further trials need to explore the feasibility and efficacy of this new assay, assess the most adequate age range for maximum effectiveness, and determine the optimal threshold for a positive result of careHPV testing in the context of primary cervical cancer screening in Africa.

We could not perform pooled analysis of predictive values of screening tests, because they are closely related to the disease prevalence. However, we used the pooled prevalence of disease obtained among studies to estimate the post-test probability of having CIN2+ or being free of disease by geographical area (fig 4[](#fig4){ref-type="fig"}, web appendix 8). The pooled positive predictive value was lower than 35% for any screening tests wherever the geographical area, suggesting that combining tests might improve the effectiveness of screening programmes. In such situations, the second test can be either an adjunct to the first, or used to select women among those who screened positive to the first test and who are at higher risk for cervical cancer and might need immediate care. Although VILI has been proposed as an adjunctive test to VIA,[@ref13] results from primary studies are controversial. A study in Colombia found that the combination of VIA and VILI performed better than VIA alone,[@ref52] whereas a recent study in Kenya found no difference.[@ref53]

![**Fig 4** Positive and negative predictive values of VIA, VILI, and HPV testing in detecting CIN2+ in sub-Saharan Africa. Curves=variation of positive and negative predictive values as a function of the prevalence of disease (CIN2+) using the Bayes'theorem, by screening test and by geographical region (western Africa, middle Africa, southern Africa, and eastern Africa). We considered the absolute sensitivity and specificity of each test to be constant and equal to the pooled values calculated with a random effects model. Prevalence of CIN2+ is shown on the x axis, and the resulting positive or negative predictive values are noted on the y axis. Heavy dotted curves=​​fitted predictive values; light dotted curves=95% confidence bands; NPV=negative predictive value; PPV=positive predictive value](domj024615.f4_default){#fig4}

Limitations of study
--------------------

VILI has never been implemented as a single test for primary screening, and has always been evaluated following VIA. Despite all precautions to ensure independence between the two tests in selected studies (such as different providers, and blinding of providers towards each test), some level of contamination cannot be eliminated. In view of the uncertainties for VILI as a standalone test, the value and limitations of using both visual methods in a sequential manner may be considered. On the other hand, studies did not provide enough data to compare screening methods' performance by HIV status, and experience and background of screeners.

HIV infection is still very common in Africa, and the prevalence of cervical dysplasia in HIV positive women reaches 50-76% in some settings.[@ref54] [@ref55] It is important to identify which screening methods are more appropriate for this high risk population. No study used histology of random cervical biopsy alone as a reference test. Although the use of a colposcopy based gold standard is likely to overestimate the accuracy of visual methods (VIA and VILI) and underestimate HPV testing's accuracy,[@ref56] [@ref57] the effect of QUADAS-2 items regarding the reference test (imperfect gold standard bias, incorporation bias, and masking towards index test) on screening tests' accuracy could not be assessed.

Conclusions and policy implications
-----------------------------------

Our findings suggest that tests qualities for VIA, VILI, and HPV testing are accurate enough for cervical cancer screening in sub-Saharan Africa, provided that adequate training and quality assurance are achieved. However, high absolute accuracy measures ​​obtained for these tests are probably misleading, given the average quality of studies and the limitations of the gold standard. Among visual methods, VILI seems to be the most sensitive test to use in the African continent. It is deemed easy to perform by Africans clinicians, and is an acceptable alternative to VIA for cervical cancer screening in this region. Finally, further studies are needed to assess the effect of screening strategies using these tests on incidence and mortality from cervical cancer in the region.

### What is already known on this topic

1.  Many trials on cervical cancer prevention have been implemented in developing countries

2.  In sub-Saharan Africa, primary data from these studies have been conflicting, with some reports concluding that visual inspection with acetic acid (VIA) is not suited for cervical cancer screening in the region

3.  Previous reviews have looked at the accuracy of alternative methods to cytology for cervical cancer screening in resource poor countries, but none has focused on sub-Saharan Africa

### What this study adds

1.  Our findings provide strong evidence that cervical visual inspection with Lugol's iodine (VILI) performs better than VIA for primary cervical cancer screening in sub-Saharan Africa

2.  As with VIA, VILI should be recommended as a suitable test for primary cervical cancer screening in sub-Saharan Africa
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